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Thalassaemia and other haemoglobinopathies constitute an important health problem in Mediterranean countries, placing a
tremendous emotional,psychological, and economicburden on their NationalHealth systems.The development of new chelators
in the most recent years had a major impact on the treatment of thalassaemia and on the quality of life of thalassaemic patients.
A new initiative was promoted by the Italian Ministry of Health, establishing a Registry for thalassaemicpatients to serve as a tool
for the development of cost-eﬀective diagnostic and therapeutic approaches and for the deﬁnition of guidelines supporting the
most appropriate management of the iron-chelating therapy and a correct use of the available iron-chelating agents. This study
represents the analysis of the preliminary data collected for the evaluation of current status of the iron chelation practice in the
Italian thalassaemicpopulation and describes how therapeutic interventions can widely diﬀer in the diﬀerent patients’ age groups.
1.Introduction
Thalassaemia major is a chronic, progressive haemoglobin
disorder requiring life-long blood transfusions. However,
in absence of an appropriate treatment, iron overload is
the clinical consequence of chronic transfusions that can
cause signiﬁcant organ damage, morbidity, and mortality.
Historical data show that iron overload in transfusion-
dependent patients not only is fatal, but causes early death
usually associated with cardiac complications [1].
Iron chelation treatment is necessary for the removal of
excess iron, but treatment’s eﬃcacy and success are highly
dependent on type and timing of the therapy as well as on
patient adherence to treatment [2–5].
Only one chelating agent, deferoxamine (DFO), was
available for many years. DFO was approved for clinical
use in patients with iron overload due to frequent blood
transfusions (including thalassaemia and other congenital
anaemia), and to date, according to the existing national or
international guidelines [6–8], it still represents the standard
iron-chelating therapy. In the last 50 years, deferoxamine
h a sp r o v e nt ob es a f ea n de ﬃcacious, radically changing
the prognosis of transfusion-dependent patients. However,
despite this benign safety and eﬃcacy proﬁle, the parental
administration, with the nuisance of an infusion pump
(for overnight subcutaneous infusion 5 to 7 nights/week),
highly prevents optimal compliance, particularly among
the youngest patients [9–13]. Moreover, almost 10–15% of
subjectsareunabletousethischelatorduetohypersensitivity2 Anemia
or toxic side eﬀects and the majority of patients refuse
DFO because of the poor quality of life associated with the
treatment.
These diﬃculties prompted in recent years the search
of an orally administrable compound. Research led to the
identiﬁcation of several interesting molecules but, among
these, only two agents became available on the European
market: deferiprone and deferasirox.
Deferiprone (DFP) was approved in 1999 and for many
years was the only oral chelator available in Europe for
the treatment of patients for whom deferoxamine was con-
traindicated or presented serious toxicity. Its use determined
signiﬁcant improvements in terms of complianceand quality
of life [14–16]. In addition, there are clinical evidences
that DFP is more eﬀective in the protection against iron
cardiotoxicity than DFO, thus increasing patient’s survival
and reducing signiﬁcant morbidity [17, 18].
These ﬁndings also stimulated the combined use of the
two drugs with the aim to obtain a global improvement and
reduced toxicity in treating iron overload. In particular, the
combination therapy originates from the observation that
patientshavevariable responses in ironexcretion and toxicity
with these twochelating agents,and their combinationcould
increase the overall iron excretion and reduce the toxicity. It
ishypothesisedthatdeferiprone,abletocrosscellmembrane,
and thus reaching pools of iron not accessible to DFO, could
shuttle tissue iron to deferoxamine in the blood stream,
where it can be chelated and eventually excreted [19, 20].
In Italy, deferiprone was introduced in 1997 within a
National Controlled Program prior to the European market-
ing authorisation approval. At that time, 532 patients from
86 clinical centres were prescribed the new oral-chelating
treatment. The Program includedpaediatric patients (10.9%
were 6–11 years of age) but no children below 6 years of age
were enrolled [21].
During the years DFP, either alone or in combination
withDFO,became thepreferred treatment forolderchildren
and adults in need to reduce cardiac iron overload. In
2010, on the basis of evidence from sponsored and sponta-
neous clinical trials, the European Medicinal Agency (EMA)
updated the registrative dossier reporting that “Data from
the published literature are consistent with the result from
the Apotex studies, demonstrating less heart disease and/or
increased survival in Ferriprox-treated patients than in those
with deferoxamine” [22].
Recentlya new oral chelator, deferasirox (DFX),has been
approved in Europe for adults and children above 6 years
when transfused with 7mL/Kg/die or more. The product is
also approved as a second line for children 2–6 years with
beta-thalassaemia and transfused with less than 7mL/Kg/die
or with other transfusion-dependent anaemia. Its long half
life (11–19 hours) allows maintaining plasma levels within
the therapeutic range for 24-hour period, permitting a con-
venient once-daily oral administration. Long-term data have
not shown any increase or unexpected adverse event with
deferasirox therapy in both paediatric and adult patients,
although some concerns have recently been raised for some
evidence of cytopenia and renal toxicity [23]. DFX seems to
be the preferred chelator in terms of compliance and quality
of life, even if the unpleasant taste and the high rate of not
serious adverse reactions of gastrointestinal nature reduce
the acceptability and the generally expected advantages.
The availability of alternative therapies, with diﬀeren-
tiated mechanism of action and tissue sensitivity, could
play a crucial role in the continuous improvement of the
thalassaemic patient’s survival and quality of life. However,
consensus guidelines on the optimal use of the available
chelators are still in preparation.
It would be of great interest to identify the characteristic
of patient populationswhich can best beneﬁt from the use of
each chelator. In lack of prospective controlled comparative
trials, we can derive useful information from the analysis of
the current use of the diﬀerent chelators and of the medical
decision underlying the prescription. The critical evaluation
of such current uses, in view of the existing guidelines and
regulatory provisions, should encourage a rationale use of
these life-saving drugs.
1.1. Aim of the Study. In Italy, the “Inter-regional Network
for Thalassaemia: HTA for the diagnostic and therapeutic
intervention for iron overload” is a project recently pro-
moted and founded by the Italian Minister of Health. Within
the framework of this project, a registry of thalassaemia
patients was designed and set up to provide a ﬂexible
platform for the assessment of the Thalassaemia major
patient’s characteristics and disease management, including
the utilization of the diﬀerent chelating agents. Other infor-
mation collected include the outcome of the treatment, the
adverse events rate, the methodologies for iron deposition
evaluation, and the cost of therapies. The project is still
ongoing and the ﬁnal results will be made public.
The present study represents a preliminary report of the
ﬁrst set of data collected in the registry. Data have been used
to perform a prevalence study aimed at evaluating
(a) the demographic characteristics of the study popula-
tion 11 and 5 years after the introduction of the two
oral chelators DFP and DFX, respectively,
(b) the current management of iron overload in a large
cohort of patients of diﬀerent age subsets.
2.Materialsand Methods
2.1. Study Design and Sites. This is a multicenter, cross-
sectional study on iron chelation treatment.
2.2. Study Population. The study population consists of sub-
jects with conﬁrmed diagnosis of beta-thalassaemia major
and under any chelation treatment in the 15 participating
Clinical Centres:
(i) Ospedale “Madonna delle Grazie” U.S. Dipartimen-
tale Ematologia-DH talassemia (Dr A. Ciancio),
(ii) A.O. Bianchi Melacrino Morelli Centro Microcitemia
(Dr. D. D’Ascola),
(iii) Ospedale “Cardarelli” UOS Talassemia Pediatrica ed
Emoglobinopatie Pediatriche (Dr. A. Filosa),Anemia 3
(iv) A.O.R.N. “Cardarelli” U.O.C. Microcitemia (Dr. L.
Prossomariti),
(v) Osp. “S. Eugenio” U.O. Day hospital Talassemia (Dr.
P. Cianciulli),
(vi) Unit` a operativa complessa di genetica ed immunolo-
gia pediatrica—Servizio di Microcitemia Azienda
Ospedaliera Universitaria “G. Martino” (Dr. B.
Piraino),
(vii) Presidio ospedaliero Centro Immunotrasfusionale
(Dr. A. Di Caro),
(viii) Centro di riferimento regionale per la diagnosi e
cura delle emoglobinopatie. A.O.V. Cervello (Dr. G.
Calvaruso),
(ix) U.O.C. Ematologia—Emoglobinopatie, Ospedale G.
Di Cristina, Azienda di Rilievo nazionale e di alta
specializzazione Civico,DiCristina, Ascoli—Palermo
(Z. Borsellino),
(x) Ospedale “Villa Soﬁa” U.O.S di talassemia (Dr. L.
Pitrolo),
(xi) P.O. “S. Bambino” U.O.C. Servizio di Talassemia (Dr.
G. Colletta),
(xii) Talassemia Azienda O.U. Policlinico (Dr. M. A.
Romeo),
(xiii) Azienda Ospedaliera O.C.R. SCIACCA U.O.S. di
T a l a s s e m i a( D r .C .G e r a r d i ) ,
(xiv) A.O. Umberto I U.O.S. Talassemia (Dr. S. Campisi),
(xv) P.O.S. Luigi—S.Curro’ U.O.D. Talassemia (Dr. S.
Anastasi).
As the project is an initiative promoted by Basilicata,
regions which were the ﬁrst to adhere to the Registry were
mainly from the south of Italy. For the aim of this study,
data are collected from these ﬁrst participant centres. To
date, other haematological clinical centres from all over
Italy adhered to the project and data collection is currently
ongoing.
Patients whounderwent bonemarrow transplantation or
takingpartininterventionalstudieshavebeenexcludedfrom
the present study.
2.3. Data Collected. Foreach patient, the following data have
been collected and analysed: (a) demographic characteristics
(age and sex), (b) anamnesis information, (c) data on
chelation therapy.
2.4. Guidelines and Approved Indications. Details on the
recommended and authorised uses of the three diﬀerent
chelators are derived by the relevant existing Guidelines
(Guidelines for the clinical management of thalassaemia.
Thalassaemia International Federation—2008 [2]; Practice
guidelines for the management of iron overload in tha-
lassaemia major and related disorders. Italian Society of
Hematology—2008 [3]; Consensus view on choice or iron
chelationtherapy intransfusional iron overloadfor inherited
anaemia, UK Forum on Haemoglobin Disorders—2008 [4])
Table 1: Thalassaemia clinical centres adhering to the study.
Region Number of clinical centres Number of patients
Sicilia 9 636 (64.8%)
Campania 2 149 (15.2%)
Lazio 1 83 (8.5%)
Calabria 1 53 (5.4%)
Basilicata 1 50 (5.1%)
Puglia 1 10 (1.0%)
Total 15 981 (100.0%)
Table 2: Demographic data of the patients participating to the
study.
Females Males Global
Sex (%) 518 (52.8%) 463 (47.2%) 981
Age: mean ± SD 31.45 ± 10.45 29.61 ±10.37 30.56 ±10.47
Median (range) 33 (2–60) 31 (2–54) 32 (2–60)
Paediatric patients (%) 53 (46.9%) 60 (53.1%) 113
and from the approved Summary of Product Characteristics
(SmPC) available in Italy for the three drugs.
2.5. Data Analysis. A descriptive analysis has been carried
out by age, gender, iron chelation agent, and referring centre
using proportions for categorical data, mean and median as
central tendency parameters for continuous data, Standard
Deviation (SD), and minimum (min) and maximum (max)
values as dispersion parameters.
Data were collected in compliance with the GCP pro-
cedures (Italian D.M. 15/07/97), the Guidelines for the
classiﬁcation and conduction of the observational clinical
studies (Italian G.U. n.76, 31/3/2008), and the Guideline for
the protection and treatment of personal data (Italian DL
196/2003).
3.Resultsand Discussion
3.1. Demographic Information. As in October 2010, a total of
981 subjects were registered in the 15 Italian Clinical Centres
participating to the Registry for Thalassaemic patients, the
majority ofwhich were locatedin the south ofItaly (Table1).
Thesmallest centrehad in care10patientsand thelargest
as many as 149 patients. The majority had in care both
paediatric and adult patients, with 4 centres having only
adult thalassaemic patients.
Demographic characteristics of the patient population
included in this study are summarised in Table 2.I n
the speciﬁc, gender distribution is balanced among males
(47.2%) and females (52.8%). The global mean age (±SD) is
30.56 ± 10.47 years, with the youngest patient aged 2 years
and the oldest patient being 60 years old. The paediatric
population represents 11.5% of the study population (113
subjects are aged 2–18 years) and 95% of the patients are 45
years of age or younger.
Details on the age distribution of patients receiving iron-
chelating therapy are illustrated in Figure 1.4 Anemia
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Figure 1: Patient distribution stratiﬁed by age and gender.
On the basis of these ﬁgures, we can derive two main
considerations. First of all it is noticeable that, despite the
numerous eﬀorts made in terms of prevention during the
years, 6% of the thalassemic population in Italy are currently
below 12 years of age and 11,5%, of patients are in the
paediatric subset.Thesecondobservationconcernsthemean
age of the patient population which is increased to 30.56 ±
10.47. It was reported that the mean age of patients shifted
from 5 years of age in 1965 to 27 years of age in 1995 [4]. As
DFX has been introduced in Italy only recently, this global
increase of the mean age can be attributed to the use of DFO
and DFP.
3.2.CurrentManagementofIronOverload. When the patient
populationincludedinthisstudy(981patients)wasanalysed
in terms of undergoing therapy, 495 patients resulted to be
under treatment with DFO (as monotherapy or combined
therapy). In detail, 271 patients (27,6% of the total) were
receiving DFO, 185 (18,9%) were treated with DFP, and
304 subjects (31,0%) were receiving DFX (Table 3). The
combination therapy with two iron-chelating agents was
administered to 221 patients (22,5%), almost exclusively as
a combination of deferoxamine and deferiprone both used
in association (12,7%) or as sequential therapy (9,5%). Only
3 (0,3%) patients in our cohort were reported to be receiving
deferoxamine and deferasirox in sequential therapy.
The analysis by centre shows a great variability in the
prescriptive approach of the chelation therapy among the
diﬀerent clinical centres. The prescription rate of DFO can
vary from 8.1% to 70.8% of patients, while the prescription
rate of DFP monotherapy ranges from 3,8% to 49.5%,
depending on the referring centre. DFX, the last approved
Table 3: Percentage of use of the diﬀerent chelating agents in the
centres participating to thestudy andhavingincare bothpaediatric
and adult patients.
Iron chelation treatment Median (%) Min–Max (%)
DFO 24.5 8.1–70.8
DFP 14.9 3.8–49.5
DFX 28.9 17.0–41.5
Combined therapy 25.4 0.0–34.2
drug, is almost exclusively used as monotherapy. Only DFO
+ DFP combined therapy appears to be more consistently
prescribed.
The distribution of diﬀerent chelating agents by age
is illustrated in Figure 2. Adult patients appear to be
equally distributed among the four available therapeutic
choices (three chelators in monotherapy plus the combined
treatment). On the contrary, in the paediatric population,
there is a clear preference for prescribing an oral chelator
(72,6%) and deferasirox is by large the preferred chelator in
this age group (64.6%).
These data indicate that many diﬀerences in terms of
prescription rate of each iron chelator exist in the diﬀerent
age groups. These diﬀerences can be explained only partially
on the basis oftheapprovedproductslabelsorofthe existing
clinical recommendations as detailed in Table 4.
In this regard, preliminary results from a structured
interview we are conducting with the participating clinical
centres which aimed to explore the medical reasons for
changing the prescribed iron chelation therapy, demonstrate
that the main reason for switching from DFO to an oral
iron chelator is almost exclusively the poor complianceAnemia 5
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Figure 2: Iron chelation treatment in the paediatric and adult
population.
associated to the parental drug in younger patients. On
the other hand, every interviewed investigator considers
cardiac iron overload the reason for initiating the simul-
taneous combination therapy (“Inter-regional Network for
Thalassaemia” project, Internal Meeting, Rome, May 2010).
This prescriptive approach conﬁrms that doctors assign
to deferiprone (mainly used in association with DFO) an
important role as iron chelator particularly in the case of
cardiac risk due to iron cardiac overload.
Figure 3 elucidates the variations among the diﬀerent
chelating treatments in the diﬀerent age groups.
In particular, the comparison of the prescription rate
derived by the present study with the recommended uses
in reported in the SmPC and guidelines highlights the
following.
2–5 Years. No more than 35% of the small group of children
below 6 years of age is currently under DFO monotherapy,
theonlyiron-chelatingagentauthorizedasaﬁrstlinetherapy
in this group of age. Over 60% of them are using an oral
chelator treatment (DFX) and, as this use is not authorized
or recommended, it should be considered as an oﬀ-label use.
In addition, the use of DFO in combination with DFP in
this age subset is very rare. As no major cardiac iron overload
is expected in this age group, monotherapy should represent
the easier and most appropriate treatment. Unfortunately, so
far the only monotherapy which demonstrated eﬃcacy and
safety in this groupof age is DFOfor which, however,nightly
subcutaneous route of administration remains an issue for
youngest patients. The poor compliance to DFO in this age
group is a problem which claims for conducting adequate
oral chelator studies in younger children.
6–11 Years. Monotherapy with an oral chelator is the most
largely used therapeutic option in this age group, with as
many as 13.5% of patients using DFP and 67.6% using DFX
(Figure 3). The prescription rates in this group demonstrate
the rapid widespread among the youngest thalassaemic
patients of the newly marketed oral-chelating agent DFX
(authorised in Europe in 2006), favoured mainly by the
convenient once-a-day administration, which allows over-
coming the compliance problems associated with DFO, and
positively compares to the three-time-a-day administration
for DFP.
12–17 Years. The chelating therapy in this age subset follows
a similar trend as above. The percentage of adolescents
receiving deferoxamine is as low as 13% and the oral
chelators are used in over 70% of teenagers and adolescents.
Combined DFO + DFP treatment in the adolescent group
stronglyincreases.Simultaneousadministration accountsfor
11.3% of the treatment in this age group and sequential
therapy for 3.8%. This data is in line with the recognised
need to start a robust iron-chelating programme in this age
group in order to avoid cardiac impairment or, in the worse
cases, to correct an overt cardiac iron overload. However, it
should be noted that the combined use (both simultaneous
and sequential) is not yet approved and spontaneous data
available on safety/eﬃcacy are to be conﬁrmed with well-
designed large controlled studies.
18–45 Years. The rate of patients treated with DFO (either
used alone or as combination therapy with DFP) increases
with the age and accounts for 30–40% of patients above 26
years of age.
It is interesting to note that the oral-chelating practice
is radically diﬀerent in older patients compared to the
y o u n g e s t .I n d e e d ,t h eu s eo fD F P( e i t h e ra l o n eo ri n
combination with DFO) represents the current therapy for
40% of transfusion-dependent thalassaemic patients above
18 years of age, while DFX is used in only 25% of patients.
Thecombinedadministration oftwochelators(DFO+DFP)
represents the therapy of choice in almost 25% as in the
adolescent group.
Finally, in our cohort two patients above 30 years of age
were reported to be treated with the DFO/DFX combined
therapy (sequential modality). However, this use is not
authorised,andappropriatestudiesarewarrantedtoevaluate
safety, eﬃcacy, and beneﬁt/risk.
>45 Years. The use of DFO (alone or in combination) still
remains thetherapyofchoiceforthalassaemic patientsabove
45 years of age, followed by DFP that is used in 24.5% of
patients. On the contrary, the use of DFX as monotherapy
becomes as low as 10%.
4.Conclusions
This study highlights how DFO is excluded from the
treatment of younger children and how oral chelators are
preferred on the basis of the expected compliance advantage,6 Anemia
Table 4: Chelators use recommendations (SmPCs and Guidelines).
Age: >2a n d<6y
SmPCs information: the onlyapproved drug in this group of age is DFO. Oral chelators can be used if DFO
is refused, inadequate, or contraindicated. No data or few data are available in children < 6y e a r sf o ro r a l
chelators (DFP and DFX). Few data between 6 and 10 years for DFP.
UK guideline: DFO is recommended as ﬁrst-line treatment, DFX as second line.
TIF guideline: DFO is recommended as ﬁrst-line treatment, oral chelators as second line. DFP above 10
years.
Italian guideline: DFO is recommendedasﬁrst-linetreatment. Theuse oforalchelators asﬁrst-linetherapy
should be considered investigational and should only be performed within clinical trials or registries.
Age: children >6yand
adults
SmPCs information: DFO and DFX approved. DFP approved if DFO is refused, inadequate, or
contraindicated. DFP demonstrated to be superior to deferoxamine in decreasing cardiac iron load.
(Ferriprox updated SmPC, 2010).
UKguideline:DFOasﬁrst-linetreatment,DFXassecondline,DFP(incombinationwithDFO)ifabnormal
cardiac function (T2∗ or ECHO or clinical symptoms).
TIF guideline: Oral chelators can be used if DFO is refused, inadequate, or contraindicated. Oﬀ label use
of DFP should be avoided. For patients with very high levels of heart iron or cardiac dysfunction, 24-hour
treatment with deferoxamine and daily therapy with deferiprone should be considered.
Italian guideline: DFO is recommended as ﬁrst-line treatment where oral chelators therapy should be
considered investigational and should only be performed within clinical trials or registries.
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Figure 3: Iron-chelating treatment stratiﬁed by age group.
despite the lack of marketing authorization approval. This
compliance beneﬁt is less recognized in the case of DFP
that is often refused for safety reasons. However, EMA
has updated the DFP SmPC, clearly indicating a potential
superiority in cardiac iron chelation, as suggested also in the
current guidelines, and it will be of interest to evaluate in
future studies if this recommendation will be applied to the
clinical practice.
Concluding, in the recent years the main changes in
prescription habits concern the dramatic increase in the use
of the newly approved oral chelator DFX; this is particularly
frequent not only among previously unchelated patients
(from 2 years of age onwards), but also in older children and
adults in substitution of DFO.
In addition, this study highlights how many patients are
stillprescribedoﬀ-label.This isthecasefortheuseoftheoral
chelator DFX in the 2–6 years age group (2,3% of the total
population and 20,3% of the paediatric population) and for
all the uses of the combined DFO+ DFP.
Finally, it is interesting to note that patients aged 45
and above appear reluctant to modify their current therapy,
mainly consisting in DFO or DFP either as monotherapyAnemia 7
or in combination. This evidence brings two signiﬁcant
implications for the patient’s prognosis and safety. On
one hand, the use of two chelators with slightly diﬀerent
mechanism of action has prolonged signiﬁcantly the overall
survival of thethalassaemic patients. The secondobservation
is that, when a-well controlled chelation is achieved, the
problem of compliance (which is almost complete in the
adult population) becomes negligible and the maintenance
ofwell beingbecomestheﬁrst objectiveforbothpatientsand
prescribers.
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